Outcomes in Patients Fully Covered With Coronary Artery Aneurysm and Stenosis Lesion by Second Generation Drug-Eluting Stents After 1 Year

Angiology ◽  
2020 ◽  
Vol 71 (10) ◽  
pp. 942-947
Author(s):  
Zhiming Wu ◽  
Chen Xu ◽  
Wei You ◽  
Fei Ye ◽  
Xiangqi Wu
Keyword(s):  
Myocardial Infarction ◽  
Coronary Artery ◽  
Second Generation ◽  
Coronary Artery Aneurysm ◽  
Artery Aneurysm ◽  
Coronary Intervention ◽  
Drug Eluting Stents ◽  
Clinical Events ◽  
Drug Eluting ◽  
One Year

We evaluated the safety and efficacy of second-generation drug-eluting stents (DES) fully covering a coronary artery aneurysm (CAA) and stenosis lesion. Patients (n = 33) with CAA and stenosis lesion (>60%) were enrolled between January 2014 and December 2017. Baseline characteristics and biochemical variables were recorded during hospital admission. Changes in CAA resolution (the reduction on CAA size), minimal lumen diameter (MLD), and diameter stenosis (DS) were determined before, just after, and 1 year after percutaneous coronary intervention (PCI). After DES implantation, MLD and DS after PCI were improved compared with those before PCI ( P < .01). Also, thrombolysis in myocardial infarction blood flow was significantly enhanced after PCI ( P < .01). One year after PCI, maximal CAA diameter in patients with CAA and stenosis lesion was significantly reduced compared with those just after PCI ( P < .01). Meanwhile, CAA resolution ratio in these patients were more than those just after PCI ( P < .01). Furthermore, there was a significant reduction about CAA length in these patients ( P < .01). Last, there were no clinical events (including cardiac death, myocardial infarction, and revascularization) in the study. Second-generation DES implantation fully covering CAA and stenosis lesion was safe and effective.

Improved clinical outcome with biodegradable polymer drug-eluting stents compared to durable polymer drug-eluting stents for primary percutaneous coronary intervention

2020 ◽  
pp. postgradmedj-2020-138243
Author(s):  
Ratna Andriyati ◽  
Doni Firman ◽  
Yovi Kurniawati ◽  
Amir Aziz Alkatiri ◽  
Raymond Pranata ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Second Generation ◽  
Coronary Intervention ◽  
Drug Eluting Stents ◽  
Recurrent Myocardial Infarction ◽  
Repeat Revascularisation ◽  
Durable Polymer ◽  
Percutaneous Coronary ◽  
Drug Eluting

BackgroundStudies comparing the clinical outcomes of second-generation biodegradable polymer drug-eluting stents (BP-DES) and second-generation durable polymer drug-eluting stents (DP-DES) in patients with ST-segment elevation myocardial infarction (STEMI) with follow-up duration of more than 1 year are still limited.ObjectiveThis study aimed to compare the 2-year clinical outcome of BP-DES with second-generation DP-DES in patients undergoing primary percutaneous coronary intervention (PPCI).MethodsThis is a retrospective cohort study in patients with STEMI, the primary endpoint was major adverse cardiac events (MACE) defined as recurrent myocardial infarction, total repeat revascularisation and cardiac death. The secondary endpoint was stent thrombosis (ST) defined as definite, probable or possible.ResultsA total of 400 patients were analysed (197 BP-DES groups and 203 DP-DES groups). BP-DES were independently associated with lower incidence of MACE (adjusted HR 0.67, 95% CI 0.21 to 0.91, p=0.005) and ST (adjusted HR 0.62, 95% CI 0.19 to 0.73, p<0.016) within 2 years of follow-up. Subgroup analysis of MACE individual components showed that BP-DES were associated with lower cardiac deaths (HR 0.35; 95% CI 0.18 to 0.94; p<0.001) compared to DP-DES, but not recurrent myocardial infarction and total repeat revascularisation.ConclusionsBP-DES were associated with better clinical outcomes compared to second-generation DP-DES in patients with STEMI undergoing PPCI.

A child case of Kawasaki with giant coronary aneurysm: percutaneous coronary intervention due to anterior myocardial infarction

2021 ◽  
pp. 1-3
Author(s):  
Mehmet Türe ◽  
Alper Akın ◽  
Faruk Ertaş ◽  
Aylin Akın Oğuz
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Coronary Artery ◽  
Coronary Arteries ◽  
Coronary Artery Aneurysm ◽  
Artery Aneurysm ◽  
Giant Aneurysm ◽  
Coronary Intervention ◽  
Anterior Myocardial Infarction ◽  
Percutaneous Coronary

Abstract Kawasaki disease is usually self-limited, but it can lead to aneurysm, stenosis, thrombosis, and myocardial infarction in the coronary arteries. The most important complication of Kawasaki disease is coronary artery aneurysm. Coronary artery aneurysm or ectasia may be seen in 15–25% of patients who do not receive treatment. It develops in 5% of children who receive intravenous immunoglobulin at the appropriate time. Acute myocardial infarction is the most important cause of morbidity and mortality in Kawasaki patients with giant aneurysms. We present a 10-year-old girl who had a history of giant aneurysm in the coronary arteries and underwent percutaneous coronary intervention due to anterior myocardial infarction.

Acute Myocardial Infarction – The Role of Drug-eluting Stents in Treatment Strategies

2011 ◽  
Vol 7 (2) ◽  
pp. 113 ◽  
Author(s):  
Ronald K Binder ◽  
Ahmed A Khattab ◽  
◽  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Coronary Artery ◽  
Treatment Strategies ◽  
Coronary Intervention ◽  
Drug Eluting Stents ◽  
Artery Dissection ◽  
Coronary Artery Dissection ◽  
St Segment Elevation ◽  
Drug Eluting

Although primary percutaneous coronary intervention (PCI) has become the cornerstone in the treatment of ST-segment elevation acute myocardial infarction (AMI), systemic fribrinolysis may still be considered for patients in areas where PCI is not accessible. The downside of initial plain balloon angioplasty, mainly coronary artery dissection and vessel re-occlusion, was effectively solved by the application of coronary stents. The incidence of target vessel failure, witnessed after bare metal stent (BMS) implantation, was dramatically reduced by the introduction of drug-eluting stents (DES), which significantly and effectively alleviate restenosis in the overall population. A minute incidence of late and very late DES thrombosis led to some safety concerns, which were soon rebutted, particularly by the development of newer generation DES. DES have consequently outplayed BMS among almost all anatomical and clinical subgroups of coronary artery disease patients. However, AMI remains one of the last contested territories. Today there is a growing body of evidence to support the use of DES as a safe and effective treatment of AMI.

scholarly journals Coronary Artery Aneurysm after Second-Generation Drug-Eluting Stent Implantation

2019 ◽  
Vol 60 (9) ◽  
pp. 824 ◽  
Author(s):  
Sung-Jin Hong ◽  
Hyoeun Kim ◽  
Chul-Min Ahn ◽  
Jung-Sun Kim ◽  
Byeong-Keuk Kim ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Stent Implantation ◽  
Second Generation ◽  
Coronary Artery Aneurysm ◽  
Artery Aneurysm ◽  
Drug Eluting Stent ◽  
Drug Eluting

Impact of the one-year angioscopic findings on long-term clinical events in 504 patients treated with first-generation or second-generation drug-eluting stents: the DESNOTE-X study

2019 ◽  
Vol 15 (7) ◽  
pp. 631-639 ◽  
Author(s):  
Yohei Sotomi ◽  
Satoshi Suzuki ◽  
Tomoaki Kobayashi ◽  
Yuma Hamanaka ◽  
Shimpei Nakatani ◽  
...  
Keyword(s):  
First Generation ◽  
Second Generation ◽  
Drug Eluting Stents ◽  
Clinical Events ◽  
Drug Eluting ◽  
One Year ◽  
The One
Sign in / Sign up

Export Citation Format

Share Document